Anna Perdrix
Founder & Co-Chief Executive Officer,
Sixfold Bioscience
Fernando Albericio
Professor,
University of KwaZulu-Natal
Joel Richard
Chief Development Officer,
Enterome
Kelly Loyet
Distinguished Scientist,
Genentech
Livija Deban
Chief Scientific Officer,
Prokarium
Maja Firczuk
Protein Expression Technologies Team Leader,
GSK
Maria Koufali
Director,
UK Vaccine Innovation Pathway
Marta Amaral
Group Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Martina Ochs
Project Leader,
CEPI
Rick Hibbert
Vice President & Head of CMC Science & Technologies,
Genmab
Sudhir Agrawal
President & Founder,
ARNAY Sciences
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Aaron John Balana
Scientist III,
Genentech
Aikaterini Gatsiou
Assistant Professor,
Lancaster University
Ajan Reginald
Chief Executive Officer,
Roquefort THerapeutics PLC
Alain Wagner
Director,
Strasbourg University
Alastair Lawson
Vice President and Immunology Fellow,
UCB
Alessandra Tolomelli
Associate Professor,
University of Bologna
Alessandro Gori
Group leader,
National Research Council of Italy
%20Cogdill.jfif)
Alexandria Cogdill
Head of Strategic Initiatives, Global Business Development,
Daiichi Sankyo, Inc
Alexey Rak
Head of Bio Structure and Biophysics,
Sanofi
Álvaro Enríquez García
Medicinal chemist,
Eli Lilly
Amita Vaidya
Principal Scientist,
Sanofi
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Andreas Reichel
Vice President, Head PMS,
Bayer AG
Andreas Midbøe Hoff
Head of In Silico & AI Department,
Nykode
Andrew Slee
Chief Operating Officer,
Protagenic Therapeutics
Andrew Jamieson
Professor,
University of Glasgow
Andrew Buchanan
Scientist,
AstraZeneca
Aneesh Karatt-Vellatt
CoFounder & CSO,
Maxion therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Full Professor and Group leader of PeptLab,
University of Florence (Italy)
Annelise Vuidepot
Chief Technology Officer,
Immunocore
Ash Otter
Principal Investigator, Emerging Pathogen Serology,
UKHSA
Baldur Sveinbjørnsson
Chief Scientific Officer,
Lytix Biopharma
Bassam Hallis
Deputy Director of Research and Evaluation,
ukhsa.gov.uk
Benjamin Lindner
Data Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Berit Olsen Krogh
Senior Research Fellow,
Lundbeck
Bernard Maillere
Head of laboratory,
CEA
Bishnu Nayak
Senior Director,
NeologicsBio
Bjorn Onfelt
Professor of Applied Physics,
Royal Institute of Technology
Brian Schanen
Global Head,
Sanofi
Bryce Nelson
Head Protein and Antibody Engineering,
Orion
Callum Scott
Head of Development,
Scancell
Carol Sze Ki Leung
Senior Immunologist,
Ludwig Institute, Oxford University
Caroline Lonez
R&D Associate Director,
Celyad
Chris Hart
Chief Executive Officer,
Creyon Bio
Christian Garde
Director,
Evaxion Biotech
Christine Dr. Rothe
Chief Development Officer (CDO),
Iomx Therapeutics Ag
Christopher Scott
Professor,
Queen's University Belfast
Christopher Coxon
Senior Lecturer, Medicinal Chemistry,
THE UNIVERSITY OF EDINBURGH
Chun Kong Mak
Oligonucleotides Analytical Scientist,
Synthon
Claudia Masini D'Avila
Principal Scientist,
Sanofi - Ghent
Dan Swerdlow
Senior Director,
GSK
Dan Hardy
CEO,
Microsol Ltd
Daniel Larocque
Innovation Leader,
Sanofi Vaccines
Daniel Sejer Pedersen
Specialist,
Novo Nordisk A/S
Darko Skegro
Associate Director,
Novartis
David Craik
Professor,
The University of Queensland
David Evans
Chief Scientific Officer,
Sirnaomics
David Brockwell
Professor,
University of Leeds
David Wraith
Professor of Immunology, Director of the Institute of Immunology and Immunotherapy,
University of Birmingham
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Group Leader,
Byondis B.V.
Elisa Marelli
Research Scientist,
Scancell
Emma Grant
Senior Analytical Development Scientist,
Immunocore
Emma Stanley
Director, Program Lead - Head of Antibody Discovery,
Mestag Therapeutics
Erik Vernet
Vice President - Scientific Data Registration,
Novo Nordisk
Fazel Shabanpoor
Lab Head Peptide And Oligonucleotide Therapeutics,
The Florey Institute of Neuroscience and Mental Health
Felix Schumacher
Program Leader Targeted Therapeutics,
Hoffmann La Roche Ltd
Francisca Wollerton
Senior Director of Protein Engineering and Novel Modalities,
AstraZeneca
Francisca Wollerton
Senior Director of Protein Engineering and Novel Modalities,
AstraZeneca
Gal Gur
VP Business Development,
Anima Biotech
Georgios Skretas
Director, Institute for Bioinnovation,
Biomedical Sciences Research Center "Alexander Fleming"
Giulio Russo
Senior Scientist,
Merus NV
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Helene Kaplon
Translational Scientist,
Servier
Henry Maun
Staff Scientist,
Genentech
Hester Van Zeeburg
PM immunomonitoring,
Mendus AB
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Ilaria Poledri
Co-Founder,
ExCulture
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Associate Principal Scientist,
AstraZeneca
Iulia Oita
CMC manager,
Ziphius Vaccines
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jean Ge
Patent Attorney,
Wolf Greenfield
Jenny Fitting
Head of AAV and Protein Science,
Bayer
Jill Walker
Immuno-Oncology Diagnostic Franchise Leader, Precision Medicine & Genomics,
AstraZeneca
John Maher
Chief Scientific Officer,
Leucid Bio
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Joost Uitdehaag
Head of Biology,
Crossfire Oncology
Jordan Davies
Campaigns,
Oxford Global
Jörg Wischhusen
Professor,
University Hospital Würzburg
.jpg?length=600&name=1048e2c3-e8c7-4b49-9c34-abc9914eac2c-2-11764368speaker_photo-Jutta-Eichler-(2).jpg)
Jutta Eichler
Professor,
University of Erlangen-Nurnberg
Karen Silence
Head Preclinical Product Development,
Argenx BVBA
Kate Smith
Senior Director, Head of UK Protein and Cell Sciences,
GSK
Kerry Chester
Professor,
UCL
Kevin Fitzgerald
Chief Scientific Officer,
Epsilogen
Kirsty Crame
Vice President Clinical Strategy & Development,
Medigene AG
Knud Jørgen Jensen
Professor,
Copenhagen University
Komal Kedia
Associate Principal Scientist,
Merck US
Kuda Muchandibaya
Lecturer for Supply Chain Management & Logistics,
Rhine-Waal University of Applied Sciences
Lada Leyens
Senior Director - EUCAN regulatory TA head GI2,
Swissmedic
Laura Starkie
Director,
UCB
Laura Collins
Director Bioinformatics,
Immunocore
Laurens Lindenburg
Principal Scientist,
Genmab
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Luis Gómez-Morales
Scientific Project Manager,
Pepkon
Mads Hald Andersen
Professor, VP,
IO Biotech
Mani Mudaliar
Director, Quantitative Biomarkers,
Exscientia
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marina Fedorova
Scientific Investigator,
GSK
Mark Eccleston
Chief Executive Officer,
ValiRx Plc.
Mathieu Cinier
Scientific Director,
Affilogic
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Micaela Graglia
Analytical Chemist, Molecular Design,
Silence Therapeutics
Michael Dyson
Vice President,
Ichnos SA
Michael Delaney
Principal Scientist,
NovoNordisk
Michal Shoshan
Founder & Chief Executive Officer,
metaLead Therapeutics AG
Mihaela Bozic
Scientist,
T-Therapeutics
Mikhail Kuravskiy
Principal Scientist,
UCB
Morten Lindow
RNAHub Founder & Mission Lead,
Roche
Nadim Akhtar
Senior Principal Scientist, New Modalities,
AstraZeneca
Nazneen Dewji
Chief Executive Officer,
Cenna Biosciences
Nesrine Chakroun
Associate Director,
Merus NV
Norbert Furtmann
Sanofi,
Head of AI Innovation NANOBODY® Platform
Obinna Ubah
Principal Scientist,
Elasmogen Limited
Owen Vickery
Computational Biologics Design,
AstraZeneca
Patricia Alves
Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,
Instituto de Biologia Experimental e Tecnológica
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Paul Reid
Chief Scientific Officer,
Celtic Biotech
Pawel Stocki
Vice President R&D,
Ossianix
Pete Gough
Chief Scientific Officer,
Nimble Therapeutics
Peter Ellmark
CSO,
Alligator Bioscience
Peter Sondermann
CEO,
Tacalyx GmbH Privacy Policy Imprint
Philip Beer
Chief Scientific Officer,
Step Pharma
Prasun Chakraborty
Chief Executive Officer and Founder,
Genevation LTD
Rajika Perera
Chief Executive Officer,
Poseidon LLC
Raymond Tesi
President & Chief Executive Officer,
InMune Bio
Reeta Daswani
Senior Scientist,
Sixfold
Rita Martello
Scientific Director, NBE DMPK Lead,
Dewpoint Therapeutics
Rodrigo Abreu
Principal Scientist,
LifeArc
Sagar Kathuria
Biophysicist - Protein Engineering,
Sanofi
Sandeep Talapatra
Science Lead - Protein Science,
GSK
Sandor Batkai
Co-founder, Head of Medical Research and Intelligence,
Cardior Pharmaceuticals GmbH
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
F. Hoffmann-La Roche Ltd
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Santiago Parpal
Principal Scientist,
Sprint Bioscience
Sarah Stuart
HTC Team Leader,
GSK
Sarah Hindson
Senior Scientist,
GSK
Saul Martinez Montero
Senior Director, RNA Therapeutics,
Dyne Therapeutics
Saurabh Sen
Associate Director, Cell Line Development, Mammalian Platform Biologics,
Sanofi
Simon Krah
Associate Director,
Merck Healthcare KgaA
Simon Plyte
Chief Scientific Officer,
Biomunex Pharmaceuticals
Simon Hufton
Section Head Molecular Immunology, Division of Biotherapeutics,
MHRA
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Head of Chemistry Research and Innovation,
Nucleic Acid Therapy Accelerator MRC
Stefan Zielonka
Director and Head of Antibody Discovery and Protein Engineering,
Merck Healthcare KGaA & Technische Universität Darmstadt
Stephen Miller
Principal Scientist,
Genentech
Stephen Sullivan
Chief Operating Officer,
iPSirius
Steve Hood
Senior Director, Oligonucleotide ADME Strategy, DMPK,
GSK
Steven Schmitt
Co-Founder & Chief Executive Officer,
Myria Biosciences
Stine Friis Thorsen
Director Clinical Development,
Evaxion Biotech
Sue Charlton
Head of Clinical Evaluation,
UKHSA
Talip Ucar
Senior Director - AI Research,
AstraZeneca
Tatyana Ponomaryov
Principal Scientist,
Plasticell Limited
Thomas Kraft
Principal Scientist,
Roche
Tim Hickling
Investigative Safety and Immunosafety Chapter Lead,
Hoffmann La Roche Ltd
Tomáš Hanke
Professor,
University of Oxford
Tomasz Witkos
Associate Director,
AstraZeneca
Trevor Smith
Vice President,
Inovio
Vincent Dewar
Head of Immunoassay,
GSK
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Vladimir Gligorijević
Senior Director, AI/ML,
Genentech
Walter Cabri
Professor,
University of Bologna
Wen Chang
Associate Vice President Discovery and Early Development,
AcuraStem
Will Nesbit
Director - Process Chemistry, CMC,
Bicycle Therapeutics
Wolfgang Koch
Senior Scientist,
F-star Therapeutics Inc
Xiao Wan
Senior Researcher - Biology,
Nucleic Acid Therapy Accelerator (NATA)
Yann Abraham
Associate Director AI for Single Cell,
Johnson & Johnson Innovative Medicine
Yi Yang
Principal Scientist,
Ferring Pharmaceuticals A/S
Zahra Rattray
Senior Lecturer,
University of Strathclyde
Who Is Sponsoring NextGen Biomed 2025?
Gold Sponsors
.png?length=600&name=1.GenScriptCorporation_Logo_EN_Horizontal_FullColor%20(2).png){kind=logo}
.png?length=600&name=download%20(35).png)
Silver Sponsors
.svg)
Alloy Therapeutics
Silver Sponsor
Alloy Therapeutics accelerates the drug discovery process by providing access to best-in-class foundational drug discovery platforms, services, and company creation capabilities. Alloy Therapeutics has developed novel strains for fully human antibody discovery and created innovative technology to support a multitude of modalities that can help to quickly identify candidates. Leveraging our world class scientists, Alloy therapeutics platforms and services enables you to build a more robust antibody-based therapeutic pipeline.
NOF Europe GmbH
Silver Sponsor
NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF's LNP platform composed of COATSOME® SS Series, novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF’s LNP platform is becoming adopted in clinical planning by NOF collaborators.
Bronze Sponsors
Bachem
Bronze Sponsor
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
Cell Signalling Technology
Bronze Sponsor
Founded by research scientists in 1999, Cell Signaling Technology (CST) is a private, family-owned company with over 400 employees worldwide. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies with high levels of specificity and lot-to-lot consistency. That’s why we produce all of our antibodies in house and perform painstaking validations for multiple applications. And the same CST scientists who produce our antibodies also provide technical support for customers, helping them design experiments, troubleshoot, and achieve reliable results.
Network & Programme Sponsors
Eurogentec S.A
Network & Programme Sponsor
Eurogentec is an international company founded in 1985 and part of Kaneka Corp. since 2010. Eurogentec is recognized as one of the major suppliers in the field of genomics (Oligonucleotides, qPCR kits & reagents) and proteomics (Custom & catalog antibodies and peptides) as well as a trusted Contract Development and Manufacturing Organization (CDMO) for the production process development and manufacturing of vaccines and medicines (therapeutic oligonucleotides, GMP plasmids, GMP recombinant proteins, mRNA…). Eurogentec provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic development.
.jpg?length=600&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
ProteoGenix SAS
Network & Programme Sponsor
ProteoGenix is a leading antibody production company founded in 2003. Our integrated solutions from gene to biotherapeutics & diagnostics make us the preferred partner of pharmaceutical & biotech companies for their custom assay development and therapeutic antibody discovery: – Antibody generation including antigen design: hybridoma technology or phage display – Antibody engineering: humanization, affinity maturation, reformatting (bispecific antibodies, ADC…), subtype or isotype switching… – Antibody production: recombinant monoclonal antibody production, stable cell line development… – Protein production: E. coli, B. subtilis, yeast, insect cells, mammalian cells – Custom peptide synthesis – Custom gene synthesis
.jpg?width=2819&height=1174&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
Novotel London West
1 Shortlands,
Hammersmith International Ctre,
London, W6 8DR
Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.
By Air
London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line - fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.
London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.
By Underground & Bus
Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.
For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.
By Rail
The closest National Rail train station is Kensington Olympia (20 minutes walk).
By Car
Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.
Parking
Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml
Information regarding accommodation for this event will be added soon
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2025, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of NextGen Biomed 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
